{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:03:17Z","timestamp":1773842597803,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1245\/s10434-025-17784-x","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T18:01:52Z","timestamp":1752688912000},"page":"8751-8758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Omission of Routine Frozen Section for Clinically Node-Negative Patients Undergoing Upfront Mastectomy Avoids Unnecessary Axillary Treatment"],"prefix":"10.1245","volume":"32","author":[{"given":"Rachel E.","family":"Sargent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea V.","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivasa V.","family":"Sevilimedu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atif J.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"17784_CR1","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/JCO.22.01565","volume":"41","author":"SAL Bartels","year":"2023","unstructured":"Bartels SAL, Donker M, Poncet C, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981\u201322023 AMAROS trial. J Clin Oncol. 2023;41:2159\u201365.","journal-title":"J Clin Oncol."},{"key":"17784_CR2","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303\u201310.","journal-title":"Lancet Oncol."},{"key":"17784_CR3","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","volume":"19","author":"V Galimberti","year":"2018","unstructured":"Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23\u201301): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1385\u201393.","journal-title":"Lancet Oncol."},{"key":"17784_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/SLA.0000000000001863","volume":"264","author":"AE Giuliano","year":"2016","unstructured":"Giuliano AE, Ballman K, McCall L, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg. 2016;264:413\u201320.","journal-title":"Ann Surg."},{"key":"17784_CR5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ejso.2016.12.011","volume":"43","author":"\u00c1 S\u00e1volt","year":"2017","unstructured":"S\u00e1volt \u00c1, P\u00e9ley G, Polg\u00e1r C, et al. Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla\u2014surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single-centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43:672\u20139.","journal-title":"Eur J Surg Oncol."},{"key":"17784_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","volume":"390","author":"J de Boniface","year":"2024","unstructured":"de Boniface J, Filtenborg Tvedskov T, Ryd\u00e9n L, et al. Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med. 2024;390:1163\u201375.","journal-title":"N Engl J Med."},{"key":"17784_CR7","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1245\/s10434-021-10726-3","volume":"29","author":"O Kantor","year":"2022","unstructured":"Kantor O, Means J, Grossmith S, et al. Optimizing axillary management in clinical T1\u20132N0 mastectomy patients with positive sentinel lymph nodes. Ann Surg Oncol. 2022;29:972\u201380.","journal-title":"Ann Surg Oncol."},{"key":"17784_CR8","doi-asserted-by":"publisher","first-page":"5978","DOI":"10.1245\/s10434-023-13898-2","volume":"30","author":"RM Pride","year":"2023","unstructured":"Pride RM, Glass CC, Nakhlis F, et al. Intraoperative pathology assessment may lead to overtreatment of the axilla in clinically node-negative breast cancer patients undergoing upfront mastectomy. Ann Surg Oncol. 2023;30:5978\u201387.","journal-title":"Ann Surg Oncol."},{"key":"17784_CR9","doi-asserted-by":"publisher","first-page":"8037","DOI":"10.1245\/s10434-022-12238-0","volume":"29","author":"AD Williams","year":"2022","unstructured":"Williams AD, Khan AJ, Sevilimedu V, Barrio AV, Morrow M, Mamtani A. Omission of intraoperative frozen section may reduce axillary overtreatment among clinically node-negative patients having upfront mastectomy. Ann Surg Oncol. 2022;29:8037\u201343.","journal-title":"Ann Surg Oncol."},{"key":"17784_CR10","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1245\/s10434-017-5960-x","volume":"24","author":"TT Nguyen","year":"2017","unstructured":"Nguyen TT, Hoskin TL, Habermann EB, Cheville AL, Boughey JC. Breast cancer-related lymphedema risk is related to multidisciplinary treatment and not surgery alone: results from a large cohort study. Ann Surg Oncol. 2017;24:2972\u201380.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"17784_CR11","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.3390\/jcm10071543","volume":"10","author":"M Le Boulc\u2019h","year":"2021","unstructured":"Le Boulc\u2019h M, Gilhodes J, Steinmeyer Z, Moli\u00e8re S, Mathelin C. Pretherapeutic Imaging for Axillary Staging in Breast Cancer: A Systematic Review and Meta-Analysis of Ultrasound, MRI and FDG PET. J Clin Med. 2021;10(7):1543.","journal-title":"J Clin Med."},{"key":"17784_CR12","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318:918\u201326.","journal-title":"JAMA."},{"key":"17784_CR13","doi-asserted-by":"crossref","unstructured":"de Wild SR, van Roozendaal LM, de Wilt JHW, et al. De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07). Br J Surg. 2024;111(4):znae077.","DOI":"10.1093\/bjs\/znae077"},{"key":"17784_CR14","doi-asserted-by":"publisher","first-page":"5623","DOI":"10.1245\/s10434-023-13568-3","volume":"30","author":"EEF Verreck","year":"2023","unstructured":"Verreck EEF, van Steenhoven JEC, Kuijer A, et al. Trends of axillary treatment in sentinel node-positive breast cancer patients undergoing mastectomy. Ann Surg Oncol. 2023;30:5623\u201332.","journal-title":"Ann Surg Oncol."},{"key":"17784_CR15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10549-019-05243-7","volume":"176","author":"A Weiss","year":"2019","unstructured":"Weiss A, Lin H, Babiera GV, et al. Evolution in practice patterns of axillary management following mastectomy in patients with 1\u20132 positive sentinel nodes. Breast Cancer Res Treat. 2019;176:435\u201344.","journal-title":"Breast Cancer Res Treat."},{"key":"17784_CR16","unstructured":"Donker M, Rutgers E, van de Velde CJ. European Cancer Congress 2013 Presidential Sessions: axillary lymph node dissection versus axillary radiotherapy: a detailed analysis of morbidity: results from the EORTC 10981\u201322023 AMAROS trial (presentation no. LBA30). Eur J Cancer. 2013;49(Suppl 3):S14."},{"key":"17784_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.breast.2022.02.013","volume":"63","author":"M Appelgren","year":"2022","unstructured":"Appelgren M, Sackey H, Wengstr\u00f6m Y, et al. Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial. Breast. 2022;63:16\u201323.","journal-title":"Breast."},{"key":"17784_CR18","unstructured":"POSNOC\u2013POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes. ClinicalTrials.gov identifier: NCT02401685. Updated 20 February 2024. Retrieved 22 September 2024 at https:\/\/clinicaltrials.gov\/study\/NCT02401685."},{"key":"17784_CR19","unstructured":"The T-REX-Trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1\u20132 sentinel node macrometastases: an open, multicenter, randomized non-inferiority phase 3 Trial. ClinicalTrials.gov identifier: NCT05634889. Updated 5 September 2024. Retrieved 22 September 2024 at https:\/\/clinicaltrials.gov\/study\/NCT05634889."},{"key":"17784_CR20","unstructured":"TAILOR RT: A randomized trial of regional radiotherapy in biomarker low-risk node-positive and T3N0 Breast Cancer. ClinicalTrials.gov identifier: NCT03488693. Updated 19 September 2024. Retrieved 22 September 2024 https:\/\/clinicaltrials.gov\/study\/NCT03488693."},{"key":"17784_CR21","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2013, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987\u201398.","journal-title":"J Clin Oncol."},{"key":"17784_CR22","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"P Rastogi","year":"2024","unstructured":"Rastogi P, O\u2019Shaughnessy J, Martin M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024;42:987\u201393.","journal-title":"J Clin Oncol."},{"key":"17784_CR23","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390:1080\u201391.","journal-title":"N Engl J Med."},{"key":"17784_CR24","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/SLA.0000000000005952","volume":"278","author":"M Coriddi","year":"2023","unstructured":"Coriddi M, Dayan J, Bloomfield E, et al. Efficacy of immediate lymphatic reconstruction to decrease incidence of breast cancer-related lymphedema: preliminary results of randomized controlled trial. Ann Surg. 2023;278:630\u20137.","journal-title":"Ann Surg."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17784-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17784-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17784-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:40:30Z","timestamp":1760715630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17784-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["17784"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17784-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The second author, Dr. Andrea V. Barrio, reports honoraria from MSD and Novartis. The fourth author, Dr. Atif J. Khan, reports intellectual property rights with Biohaven Pharmaceuticals, Professional Services and Activities with Exact Sciences Corporation, and Equity with Xtrava. The fifth author, Dr. Monica Morrow, reports honoraria from Merck. The other authors have no conflicts of interest to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}